Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth1 Approval is based on interim data from ongoin...
These models are essential for testing in vivo efficacy of novel therapeutics against lung cancer, elevating the prospects for significant advances in the ...
Boston Scientific Corporation (NYSE: BSX) announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed F...
Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced that the company has entered into a multi-million-dollar distributi...
“We took a big step forward in our ongoing commitment to deliver sustainable solutions to our customers, quantifying the impact of our proprietary ap...
STARLIMS, a leading provider of enterprise informatics solutions, announces the expansion of its solution suite through the strategic acquisition of Labste...
DE refers to the exemption of medical devices intended for marketing from regulatory requirements, allowing clinical trials to be conducted on such devices...
Acorai is developing a first-of-its-kind, scalable medical device for non-invasive intracardiac pressure monitoring to improve heart failure management for...
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial inte...
This patent is expected to expire no earlier than June 2035. The allowed claims cover the use of MN-001 (tipelukast) for inhibiting or treating sclero...
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in d...
QIAGEN announced the U.S. Food and Drug Administration (FDA) approval of its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit). This companion diagn...
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22...
“We are pleased to announce the closing of this acquisition, as the brands we are adding will strengthen, complement and expand STERIS’s produc...
© 2025 Biopharma Boardroom. All Rights Reserved.
